Reports
Sale
Liver Fibrosis Market Share, Trends, Analysis, Forecast: By Condition: Chronic Liver Diseases, Hepatitis C, Nonalcoholic Steatohepatitis; By Treatment: Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist, ACE Inhibitors, Hepatotropic Drug, Others; By Distribution Channel; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Liver Fibrosis Market Outlook
The liver fibrosis market size was valued at USD 2317.7 million in 2023, driven by the increasing incidence and awareness of liver fibrosis among people. The market size is anticipated to grow at a CAGR of 7.7% during the forecast period of 2024-2032 to achieve a value of USD 4518.6 million by 2032.
Liver Fibrosis: Introduction
Fibrosis refers to the thickening or scarring of tissues. Fibrosis makes the essential structures of the liver lose their delicacy, followed by which they become thick, stiff, and scarred. When it comes to the liver, fibrosis involves the excessive formation of scar tissue. This occurs when the liver undergoes attempts at self-repair and cell replacement due to damage. Typically, after a singular instance of injury, such as with acute hepatitis, the liver's natural response involves generating new cells and integrating them into the remaining connective tissue framework, left behind after cell death.
However, in cases of repeated or ongoing damage, as observed in chronic hepatitis, the liver's repair efforts result in the formation of scar tissue—fibrosis. Fibrosis signifies an abnormal response to damage, wherein the body's attempt at healing leads to the formation of scar tissue, altering the structure and functionality of the affected organ.
Liver Fibrosis Market Analysis
The liver fibrosis market is experiencing significant market growth driven by the increased prevalence of liver fibrosis. The market growth is also driven by several innovations and novel therapies targeted toward treating such complex conditions. A recent update by Intercept Pharmaceuticals on the FDA accepting their New Drug Application (NDA) for obeticholic acid (OCA) marks a pivotal moment in addressing pre-cirrhotic liver fibrosis due to non-alcoholic steatohepatitis (NASH). This acceptance by the FDA not only expands treatment options but also fills a crucial gap, offering the first approved treatment specifically targeting this stage of liver fibrosis. The competitive landscape is expected to evolve with the introduction of other drugs like OCA and resmethrin, as both are known to address the same concern with different mechanisms, further influencing the liver fibrosis market growth.
Researchers are delving deep into various approaches, exemplified by the exploration of a hormone-mimicking drug by the University of California San Diego School of Medicine, that showcased promising results, demonstrating improvements in liver fibrosis and inflammation among NASH patients. This study underscores the dedication and depth of comprehension researchers are demonstrating in their efforts to provide effective treatments for this condition, which currently lacks approved therapies. These increasing innovations and advancements are exhibiting further potential markets for growth in the forecast period. The focused efforts of pharmaceutical companies, coupled with research institutions, indicate a growing understanding of the complexities of liver fibrosis exhibiting the need for new treatment approaches and drug pipelines.
Liver Fibrosis Market Segmentations
Market Breakup by Condition
- Chronic Liver Diseases
- Hepatitis C
- Nonalcoholic Steatohepatitis
Market Breakup by Treatment
- Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
- ACE Inhibitors
- Hepatotropic Drug
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Stores and Pharmacy
- Online Providers
Market Breakup by End User
- Hospitals
- Clinics
- Others
Market Breakup by -7MM
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Liver Fibrosis Market Overview
The market in the 7 major markets is witnessing substantial growth propelled by the escalating prevalence of liver-related conditions worldwide. The increasing efforts of research organizations focusing on developing treatments for fatty liver diseases are also expected to further propel the liver fibrosis market growth significantly.
Moreover, the rising mortality rates due to liver diseases and the increasing incidence of liver cancer emphasize the urgent need for advanced treatments. The data from the United States substantial data exhibits how there is an existing urgent demand for effective treatments and interventions in the market to address the growing health concerns associated with liver diseases.
Liver Fibrosis Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- F. Hoffmann-La Roche
- Mylan N.V.
- Sanofi
- GlaxoSmithKline plc
- AstraZeneca
- Johnson & Johnson
- Merck & Co.
- Bristol-Myers Squibb
- Vertex Pharmaceuticals
- FibroGen, Inc.
- Pharmaxis
- Dicerna Pharmaceuticals, Inc.
- Dynavax Technologies
- GlaxoSmithKline plc
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Condition |
|
| Breakup by Treatment |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Liver Fibrosis Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Success Rate
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Liver Fibrosis Epidemiology Analysis – 7MM
6.1 7MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Liver Fibrosis Epidemiology Forecast (2017-2032)
6.3 EU-4 and United Kingdom Liver Fibrosis Epidemiology Forecast (2017-2032)
6.3.1 Germany Liver Fibrosis Epidemiology Forecast (2017-2032)
6.3.2 France Liver Fibrosis Epidemiology Forecast (2017-2032)
6.3.3 Italy Liver Fibrosis Epidemiology Forecast (2017-2032)
6.3.4 Spain Liver Fibrosis Epidemiology Forecast (2017-2032)
6.3.5 United Kingdom Liver Fibrosis Epidemiology Forecast (2017-2032)
6.4 Japan Liver Fibrosis Epidemiology Forecast (2017-2032)
7 Liver Fibrosis Market Overview – 7MM
7.1 Liver Fibrosis Market Historical Value (2017-2023)
7.2 Liver Fibrosis Market Forecast Value (2024-2032))
8 Liver Fibrosis Market Landscape-7MM
8.1 Liver Fibrosis Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Liver Fibrosis Market: Product Landscape
8.2.1 Analysis by Drug Class
8.2.2 Analysis by Route of Administration
9 Liver Fibrosis Treatment Challenges and Unmet Needs
9.1 Treatment Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Treatment
11 Liver Fibrosis Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.3 Porter’s Five Forces Model
11.4 Key Demand Indicators
11.5 Key Price Indicators
11.6 Industry Events, Initiatives, and Trends
11.7 Value Chain Analysis
12 Liver Fibrosis Market Segmentation -7MM
12.1 Liver Fibrosis Market by Condition
12.1.1 Market Overview
12.1.2 Chronic Liver Diseases
12.1.3 Hepatitis C
12.1.4 Nonalcoholic Steatohepatitis
12.2 Liver Fibrosis Market by Treatment
12.2.1 Market Overview
12.2.2 Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
12.2.3 ACE Inhibitors
12.2.4 Hepatotropic Drug
12.2.5 Others
12.3 Liver Fibrosis Market by Distribution Channel
12.3.1 Market Overview
12.3.2 Hospital pharmacies
12.3.3 Retail Stores and Pharmacy
12.3.4 Online Providers
12.4 Liver Fibrosis Market by End User
12.4.1 Market Overview
12.4.2 Hospitals
12.4.3 Clinics
12.4.4 Others
12.5 Liver Fibrosis Market by Region
12.5.1 Market Overview
12.5.2 United States
12.5.3 EU-4 and the United Kingdom
12.5.3.1 Germany
12.5.3.2 France
12.5.3.3 Italy
12.5.3.4 Spain
12.5.3.5 United Kingdom
12.5.4 Japan
13 United States Liver Fibrosis Market
13.1 Liver Fibrosis Market Historical Value (2017-2023)
13.2 Liver Fibrosis Market Forecast Value (2024-2032)
13.2.1 Liver Fibrosis Market by Disease Type
13.2.2 Liver Fibrosis Market by Treatment Type
14 EU-4 and United Kingdom Liver Fibrosis Market
14.1 Liver Fibrosis Market Historical Value (2017-2023)
14.2 Liver Fibrosis Market Forecast Value (2024-2032)
14.3 Germany Liver Fibrosis Market Overview
14.3.1 Liver Fibrosis Market by Disease Type
14.3.2 Liver Fibrosis Market by Treatment Type
14.4 France Liver Fibrosis Market Overview
14.4.1 Liver Fibrosis Market by Disease Type
14.4.2 Liver Fibrosis Market by Treatment Type
14.5 Italy Liver Fibrosis Market Overview
14.5.1 Liver Fibrosis Market by Disease Type
14.5.2 Liver Fibrosis Market by Treatment Type
14.6 Spain Liver Fibrosis Market Overview
14.6.1 Liver Fibrosis Market by Disease Type
14.6.2 Liver Fibrosis Market by Treatment Type
14.7 United Kingdom Liver Fibrosis Market Overview
14.7.1 Liver Fibrosis Market by Disease Type
14.7.2 Liver Fibrosis Market by Treatment Type
15 Japan Liver Fibrosis Market
15.1 Liver Fibrosis Market Historical Value (2017-2023)
15.2 Liver Fibrosis Market Forecast Value (2024-2032)
15.2.1 Liver Fibrosis Market by Disease Type
15.2.2 Liver Fibrosis Market by Treatment Type
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 F. Hoffmann-La Roche
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Mylan N.V.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Sanofi
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 GlaxoSmithKline plc
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 AstraZeneca
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Johnson & Johnson
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Merck & Co.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Bristol-Myers Squibb
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Vertex Pharmaceuticals
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 FibroGen, Inc.
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Pharmaxis
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Dicerna Pharmaceuticals, Inc.
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Dynavax Technologies
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 GlaxoSmithKline plc
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
22 Liver Fibrosis Market - Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 2317.7 million in 2023, driven by an increased need for new treatments.
The market is anticipated to grow at a CAGR of 7.7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 4518.6 million by 2032.
The rising disposable incomes of the patients, expanding healthcare infrastructure, increasing prevalence of liver-related conditions and increasing advancements in the market are the key factors driving the market growth.
The increasing number of research activities by the research institutes is a key trend influencing the market growth.
The 7 major regions of the market include the United States, EU-4 and the United Kingdom, and Japan.
Types of liver fibrosis include chronic liver diseases, hepatitis C, and nonalcoholic steatohepatitis.
Available treatments include peroxisome proliferator-activated receptors (PPAR)-alpha agonists, ace inhibitors, and hepatotropic drugs, among others.
Distribution channels include hospital pharmacies, retail stores, pharmacies, and online providers.
End users in the market include hospitals and clinics, among others.
Key players involved in the market are F. Hoffmann-La Roche, Mylan N.V., Sanofi, GlaxoSmithKline plc, AstraZeneca, Johnson & Johnson, Merck & Co., Bristol-Myers Squibb, Vertex Pharmaceuticals, FibroGen, Inc., Pharmaxis, Dicerna Pharmaceuticals, Inc., Dynavax Technologies, and GlaxoSmithKline plc.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER